Holen Sie sich die Stockscreener-App
3.455
0.43%
-0.015
Schlusskurs vom Vortag:
$3.47
Offen:
$3.48
24-Stunden-Volumen:
13,666
Relative Volume:
0.24
Marktkapitalisierung:
$22.52M
Einnahmen:
$5.75M
Nettoeinkommen (Verlust:
$-38.96M
KGV:
-0.2771
EPS:
-12.47
Netto-Cashflow:
$-32.63M
1W Leistung:
+1.02%
1M Leistung:
-50.66%
6M Leistung:
-32.41%
1J Leistung:
-49.47%
1-Tages-Spanne:
$3.40
$3.54
1-Wochen-Bereich:
$3.35
$3.85
52-Wochen-Spanne:
$3.35
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Vergleichen Sie KALA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.455 | 22.52M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
Oppenheimer maintains Kala Bio stock Outperform with $15 target By Investing.com - Investing.com Canada
Kala Bio announces executive retention bonuses - Investing.com Australia
KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com - Investing.com South Africa
Kala Bio announces executive retention bonuses By Investing.com - Investing.com South Africa
Kala Pharmaceuticals Announces Executive Retention Agreements - TipRanks
KALA stock touches 52-week low at $3.4 amid market challenges - Investing.com
Darling Ingredients Inc. (NYSE:DAR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Truist Financial Lowers Bank of New York Mellon (NYSE:BK) Price Target to $90.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA) - Defense World
Kala Pharmaceuticals stock hits 52-week low at $4.05 - Investing.com India
Kala Pharmaceuticals stock hits 52-week low at $4.05 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Kala Bio, target at $15 By Investing.com - Investing.com Canada
Kala Bio Inc Reports Q4 2024 Earnings: EPS Misses Estimate at -2 - GuruFocus
Simply Good Foods (SMPL) Expected to Announce Earnings on Wednesday - The AM Reporter
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock - Investing.com Australia
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock By Investing.com - Investing.com UK
KALA BIO: Q4 Earnings Snapshot - Huron Daily Tribune
KALA BIO Advances Eye Disease Therapies with New Funding - TipRanks
KALA BIO Inc. (KALA) reports earnings - Quartz
KALA BIO, Inc. SEC 10-K Report - TradingView
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
KALA BIO (KALA) Projected to Post Quarterly Earnings on Friday - Defense World
KALA BIO Inc expected to post a loss of $2.28 a shareEarnings Preview - TradingView
Comprehensive Insights of the Global Acute Ocular Pain Market: Key Drivers, Trends, Growth Opportunities, a... - WhaTech
KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Kala Bio appoints new interim CEO amid leadership shuffle - MSN
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference - TradingView
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - The Manila Times
What Will KALA BIO Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction - MSN
Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - The Manila Times
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
KALA BIO's (KALA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Kala Bio Inc (NASDAQ: KALA) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
KALA BIO says CEO Mark Iwicki resigns - MSN
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kala Bio Inc-Aktie (KALA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brazzell Romulus K | SEE REMARKS |
Jan 06 '25 |
Sale |
7.63 |
2,446 |
18,663 |
92,418 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jan 06 '25 |
Sale |
7.63 |
5,779 |
44,094 |
280,076 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jan 06 '25 |
Sale |
7.63 |
1,706 |
13,017 |
68,581 |
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):